{"analyses":[{"ciLowerLimit":"-0.468","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.424","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.228","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.92","paramType":"Slope","paramValue":"-0.022","statisticalComment":"The treatment effect was determined by testing the significance of the group by time interaction in GEE using a one degree-of-freedom (df) test.","statisticalMethod":"Generalized Estimating Equation (GEE)"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.2625","value":"4.4464"},{"groupId":"OG001","spread":"0.6531","value":"5.2538"}]}],"title":"BL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.2519","value":"4.3252"},{"groupId":"OG001","spread":"0.2746","value":"4.3735"}]}],"title":"6m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.234","value":"3.7345"},{"groupId":"OG001","spread":"0.327","value":"4.3415"}]}],"title":"12m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.2482","value":"3.4548"},{"groupId":"OG001","spread":"0.2506","value":"4.0214"}]}],"title":"18m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.3099","value":"3.8073"},{"groupId":"OG001","spread":"0.2853","value":"4.0791"}]}],"title":"24m"}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"description":"A protein produced by activated macrophages, and a member of a family of β-galactoside-binding lectings and promotes cardiac fibroblast proliferation and collagen synthesis following myocadial injury (in ng/ml). The mean is reported by arm at each timepoint with corresponding standard errors.","dispersionType":"Standard Error","groups":[{"description":"Patients received Carvedilol PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.","id":"OG000","title":"Arm I (Carvedilol)"},{"description":"Patients received Placebo PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.","id":"OG001","title":"Arm II (Placebo)"}],"paramType":"MEAN","populationDescription":"We excluded 31 participants who did not have a second time point assessment of echocardiography, resulting in 151 analyzable participants.","reportingStatus":"POSTED","timeFrame":"Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation","title":"Average Galectin-3","type":"SECONDARY","unitOfMeasure":"ng/mL"}